摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-吡咯啉-1-基苯胺 | 21627-58-7

中文名称
2-吡咯啉-1-基苯胺
中文别名
2-吡咯烷-1-苯胺;2-吡咯烷-1-基苯胺
英文名称
2-(pyrrolidin-1-yl)-phenylamine
英文别名
2-(pyrrolidin-1-yl)aniline;o-pyrrolidinyl aniline;2-pyrrolidin-1-ylaniline
2-吡咯啉-1-基苯胺化学式
CAS
21627-58-7
化学式
C10H14N2
mdl
MFCD03563756
分子量
162.235
InChiKey
BFPUBGCFJMIZDF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    29.3
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险品运输编号:
    NONH for all modes of transport
  • 海关编码:
    2933990090
  • 危险标志:
    GHS07
  • 危险性描述:
    H319
  • 危险性防范说明:
    P305 + P351 + P338

SDS

SDS:13a8c477bb51ea15d84636cbe7d9ff8b
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Pyrrolidinoaniline
Synonyms: 2-Pyrrolidin-1-ylaniline

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Pyrrolidinoaniline
CAS number: 21627-58-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H14N2
Molecular weight: 162.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-吡咯啉-1-基苯胺硫酸 、 sodium nitrite 、 potassium iodide 作用下, 以 为溶剂, 反应 3.5h, 以12%的产率得到1-(2-iodo-phenyl)-pyrrolidine
    参考文献:
    名称:
    EP3239143
    摘要:
    公开号:
  • 作为产物:
    描述:
    硝基氯苯copper(l) iodide乌洛托品 、 palladium on activated charcoal 、 caesium carbonate一水合肼 作用下, 以 乙醇N,N-二甲基甲酰胺 为溶剂, 反应 28.0h, 生成 2-吡咯啉-1-基苯胺
    参考文献:
    名称:
    新型3-(二氟甲基)-1-甲基-1H-吡唑-4-羧酸酰胺的合成,抗真菌活性和结构活性关系
    摘要:
    合成了一系列新型的3-(二氟甲基)-1-甲基-1H-吡唑-4-羧酸酰胺,并通过体外菌丝体生长抑制试验测试了它们对七种植物病原真菌的活性。他们大多数表现出中等至出色的活动。其中N-(2-(5-溴-1H-吲唑-1-基)苯基)-3-(二氟甲基)-1-甲基-1H-吡唑-4-羧酰胺(9m)具有较高的抗真菌活性七种植物病原性真菌要比Boscalid好。用Topomer CoMFA建立了化合物的三维定量构效关系模型。在分子对接中,9m的羰基氧原子可与SDH上的TYR58和TRP173的羟基形成氢键。
    DOI:
    10.3390/molecules20058395
点击查看最新优质反应信息

文献信息

  • Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
    申请人:Vertex Pharmaceuticals Incorporated
    公开号:US20150231142A1
    公开(公告)日:2015-08-20
    The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
    本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物(A式、B式、C式或D式)的药物组合物。该发明还涉及这些药物配方,以及使用这些组合物治疗CFTR介导的疾病,特别是囊性纤维化的方法。
  • Imidazoline derivatives as alpha-1A adrenoceptor ligands
    申请人:Bigham Eric Cleveland
    公开号:US06884801B1
    公开(公告)日:2005-04-26
    Compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed. Such compounds are useful in the treatment of Alpha-1A mediated diseases or conditions such as urinary incontinence.
    化合物的化学式(I)或其药用可接受的盐或溶剂的复合物已被披露。这些化合物在治疗Alpha-1A介导的疾病或症状,如尿失禁方面是有用的。
  • [EN] BRUTON'S TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE DE BRUTON
    申请人:BIOGEN IDEC INC
    公开号:WO2011029046A1
    公开(公告)日:2011-03-10
    The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
    本发明提供了用作Btk抑制剂的化合物、其组合物以及使用方法。
  • [EN] COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES CUTANÉS
    申请人:KAMARI PHARMA LTD
    公开号:WO2021154966A1
    公开(公告)日:2021-08-05
    Provided herein is a compound of formula (XXXII) or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer thereof or a physiologically functional derivative thereof, wherein R1, R2, R3, G, A, E, n, p, and q are defined herein. Also provided herein are compositions comprising a compound of formula (XXXII), and methods of using a compound of formula (XXXII), e.g., in the treatment or prevention of skin disorders.
    提供了一种公式(XXXII)的化合物或药用可接受的盐、溶剂化物、水合物、立体异构体或生理功能衍生物,其中R1、R2、R3、G、A、E、n、p和q在此定义。此外,还提供了包含公式(XXXII)化合物的组合物,以及使用公式(XXXII)化合物的方法,例如,在治疗或预防皮肤病中的应用。
  • [EN] SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF<br/>[FR] PETITES MOLÉCULES AGONISTES DE LA MUCOLIPINE 1 ET LEURS UTILISATIONS
    申请人:UNIV MICHIGAN REGENTS
    公开号:WO2021041866A1
    公开(公告)日:2021-03-04
    This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a phenyl-sulfonic amide (or similar) structure which function as agonists of mucolipin 1 (ML1), and their use as therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and related disorders.
    这项发明属于药物化学领域。特别是,该发明涉及一类新的小分子,具有苯磺酰胺(或类似)结构,作为肌球脂蛋白1(ML1)的激动剂,以及它们作为治疗杜氏肌肉萎缩症(DMD)和相关疾病的疗法的用途。
查看更多

同类化合物

(2R,2''R)-(-)-2,2''-联吡咯烷 麦角甾-7,22-二烯-3-基亚油酸酯 马来酰亚胺霉素 马来酰亚胺基甲基-3-马来酰亚胺基丙酸酯 马来酰亚胺丙酰基-dPEG4-NHS 马来酰亚胺-酰胺-PEG6-琥珀酰亚胺酯 马来酰亚胺-酰胺-PEG24-丙酸 马来酰亚胺-酰胺-PEG12-丙酸 马来酰亚胺-四聚乙二醇-羧酸 马来酰亚胺-四聚乙二醇-丙酸叔丁酯 马来酰亚胺-六聚乙二醇-丙酸叔丁酯 马来酰亚胺-二聚乙二醇-丙酸叔丁酯 马来酰亚胺-三(乙烯乙二醇)-丙酸 马来酰亚胺-一聚乙二醇-羧酸 马来酰亚胺-一聚乙二醇-丙烯酸琥珀酰亚胺酯 马来酰亚胺-PEG3-羟基 马来酰亚胺-PEG2-胺三氟醋酸盐 马来酰亚胺-PEG2-琥珀酰亚胺酯 马来酰亚胺 频哪醇硼酸酯 顺式4-甲基吡咯烷酮-3-醇盐酸盐 顺式3,4-二氨基吡咯烷-1-羧酸叔丁酯 顺式-二甲基 1-苄基吡咯烷-3,4-二羧酸 顺式-N-[2-(2,6-二甲基-1-哌啶基)乙基]-2-氧代-4-苯基-1-吡咯烷乙酰胺 顺式-N-Boc-吡咯烷-3,4-二羧酸 顺式-5-苄基-2-叔丁氧羰基六氢吡咯并[3,4-c]吡咯 顺式-4-氧代-六氢-吡咯并[3,4-C]吡咯-2-甲酸叔丁酯 顺式-3-氟-4-羟基吡咯烷-1-羧酸叔丁酯 顺式-3-氟-4-甲基吡咯烷盐酸盐 顺式-2-甲基六氢吡咯并[3,4-c]吡咯 顺式-2,5-二甲基吡咯烷 顺式-1-苄基-3,4-吡咯烷二甲酸二乙酯 顺式-(9CI)-3,4-二乙烯-1-(三氟乙酰基)-吡咯烷 顺-八氢环戊[c]吡咯-5-酮盐酸盐 非星匹宁 阿维巴坦中间体1 阿曲生坦中间体 阿曲生坦 间甲氧基苯乙腈 铂(2+)羟基乙酸酯-吡咯烷-3-胺(1:1:1) 钾2-氧代吡咯烷-1-磺酸酯 钠1-[(9E)-9-十八碳烯酰基氧基]-2,5-二氧代-3-吡咯烷磺酸酯 金刚烷-1-基(吡咯烷-1-基)甲酮 酸-1-吡咯烷-1,4-氨基-2-甲基-1,1,1-二甲基乙基酯,(2S,4R)- 酚丙氢吡咯 试剂3-Mercaptopropanyl-N-hydroxysuccinimideester 西他利酮 血红素酸 螺虫乙酯残留代谢物Mono-Hydroxy 萘吡坦